{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T18:16:01Z","timestamp":1725473761539},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jprot.2011.11.010","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T19:40:50Z","timestamp":1321904450000},"page":"1401-1410","source":"Crossref","is-referenced-by-count":10,"title":["Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms"],"prefix":"10.1016","volume":"75","author":[{"given":"Kazuyasu","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenobu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2011.11.010_bb0005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jprot.2011.11.010_bb0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jprot.2011.11.010_bb0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cc.4.4.1564","article-title":"Histone deacetylase inhibitors in programmed cell death and cancer therapy","volume":"4","author":"Marks","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jprot.2011.11.010_bb0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jprot.2011.11.010_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/13543784.2010.504710","article-title":"Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas","volume":"19","author":"Watanabe","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jprot.2011.11.010_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-008-0747-1","article-title":"Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas","volume":"63","author":"Erlich","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jprot.2011.11.010_bb0035","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jprot.2011.11.010_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3727\/096504007783338340","article-title":"Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines","volume":"16","author":"Ciusani","year":"2007","journal-title":"Oncol Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0050","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pmic.200900602","article-title":"Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells","volume":"10","author":"Zhou","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.bbapap.2008.04.022","article-title":"A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells","volume":"1784","author":"Milli","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jprot.2011.11.010_bb0065","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1021\/pr800510p","article-title":"Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry","volume":"7","author":"Lee","year":"2008","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0070","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/sj.leu.2404902","article-title":"Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells","volume":"21","author":"Sanda","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jprot.2011.11.010_bb0075","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1021\/pr1005263","article-title":"Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells","volume":"9","author":"Fuller","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0080","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/pmic.200701089","article-title":"Synergistic effect of trichostatin A and 5-aza-2\u2032-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study","volume":"9","author":"Cecconi","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0085","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.leukres.2011.01.033","article-title":"Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid","volume":"35","author":"Buchi","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0090","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1002\/pmic.200600097","article-title":"Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2-D DIGE and MS","volume":"6","author":"Fujii","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pmic.200401004","article-title":"Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye","volume":"5","author":"Fujii","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1982.tb05085.x","article-title":"Sodium valproate: monotherapy and polytherapy","volume":"23","author":"Covanis","year":"1982","journal-title":"Epilepsia"},{"key":"10.1016\/j.jprot.2011.11.010_bb0105","first-page":"89","article-title":"Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?","volume":"1816","author":"Khalil","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jprot.2011.11.010_bb0110","first-page":"2942","article-title":"Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells","volume":"60","author":"Yokota","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0115","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT","volume":"226","author":"Bruzzese","year":"2011","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jprot.2011.11.010_bb0120","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/JTO.0b013e318220caff","article-title":"Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation","volume":"6","author":"Seo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jprot.2011.11.010_bb0125","first-page":"1115","article-title":"Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines","volume":"31","author":"Yang","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jprot.2011.11.010_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/epr.09.87","article-title":"Cancer proteome-expression database: genome medicine database of Japan proteomics","volume":"7","author":"Kondo","year":"2010","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000245893","article-title":"Protein expression in human non-small cell lung cancer: a systematic database","volume":"76","author":"Buhrens","year":"2009","journal-title":"Pathobiology"},{"key":"10.1016\/j.jprot.2011.11.010_bb0140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/pmic.200401346","article-title":"Database of two-dimensional polyacrylamide gel electrophoresis of proteins labeled with CyDye DIGE Fluor saturation dye","volume":"6","author":"Fujii","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchromb.2005.05.024","article-title":"Two-dimensional electrophoresis database of fluorescence-labeled proteins of colon cancer cells","volume":"823","author":"Mori","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jprot.2011.11.010_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4172\/jpb.1000106","article-title":"Proteome expression database of lund adenocarcinoma: a segment of the Genome Medicine Database of Japan Proteomics","volume":"2","author":"Kosaihira","year":"2009","journal-title":"J Proteome Bioinform"},{"key":"10.1016\/j.jprot.2011.11.010_bb0155","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4172\/jpb.1000112","article-title":"Proteome expression database of ewing sarcoma: a segment of the Genome Medicine Database of Japan Proteomics","volume":"2","author":"Kikuta","year":"2009","journal-title":"J Proteomics Bioinform"},{"key":"10.1016\/j.jprot.2011.11.010_bb0160","doi-asserted-by":"crossref","first-page":"001","DOI":"10.4172\/jpb.1000057","article-title":"The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis","volume":"02","author":"Yamada","year":"2009","journal-title":"J Proteomics Bioinform"},{"key":"10.1016\/j.jprot.2011.11.010_bb0165","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1002\/pmic.200500883","article-title":"Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis","volume":"6","author":"Okano","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2011.11.010_bb0170","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/sj.onc.1207529","article-title":"Molecular chaperones and the stress of oncogenesis","volume":"23","author":"Mosser","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jprot.2011.11.010_bb0175","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nrc1505","article-title":"The role of the unfolded protein response in tumour development: friend or foe?","volume":"4","author":"Ma","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jprot.2011.11.010_bb0180","doi-asserted-by":"crossref","first-page":"794901","DOI":"10.1155\/2009\/794901","article-title":"Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma","volume":"2009","author":"Nguyen","year":"2009","journal-title":"Sarcoma"},{"key":"10.1016\/j.jprot.2011.11.010_bb0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3892\/mmr_000000262","article-title":"Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line","volume":"3","author":"Yerlikaya","year":"2010","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jprot.2011.11.010_bb0190","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1074\/jbc.M107942200","article-title":"Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70","volume":"277","author":"Johnson","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187439191100635X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187439191100635X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T14:30:38Z","timestamp":1639751438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187439191100635X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S187439191100635X"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2011.11.010","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}